The number of patients undergoing solid organ transplantation is increasing. Invasive fungal infection (IFI) is an important cause of graft loss and mortality in these patients. Invasive candidiasis is the most common IFI in solid organ transplant recipients. Because of lack of randomized controlled trials, antifungal treatments should be performed as recommended for other immunosuppressed hosts. Drug interactions should be considered when using azol groups.